Chemoprevention of melanoma: An unexplored strategy

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 158-165

  Demierre, Marie France ^a,b   Nathanson, Larry ^a  

^a Boston University Medical Campus   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL; DRUG DESIGN; GENETICS; HUMAN; MELANOMA; METHODOLOGY; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; MELANOMA; MODELS, GENETIC;

EID: 0037208534     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.173     Document Type: Article

References (103)

1. Howe HL, Wingo PA, Thun MJ, et al: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824-842, 2001.
2. Jemal A, Thomas A, Murray T, et al: Cancer statistics 2002. CA Cancer J Clin 52:23-47, 2002.
3. Anti-Cancer Council of Victoria: SunSmart Campaign 2000-03, Melbourne, Australia, Anti-Cancer Council, 2000.
4. Mettlin CJ: Skin cancer and ozone depletion: The case for global action. J Surg Oncol 77:76-78, 2001.
5. Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues. Fed Proc 35:1332- 1338, 1976.
6. Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: Progress and promise. J Natl Cancer Inst 90:1514-1528, 1998.
7. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al: Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 8:314-346, 2002.
8. Viner JL, Lawrence J, Richmond E, et al: Chemoprevention, in Alison MR (ed): The Cancer Handbook, London, Nature Scientific American Publishing Group, 2001, pp 1417-1437.
9. Lippman SM, Hong WK: Cancer prevention by delay. Clin Cancer Res 8:305-313, 2002.
10. Armstrong BK, Kricker A: How much melanoma is caused by sun exposure? Melanoma Res 3:395-401, 1993.
11. Gilchrest BA, Eller MS, Geller AC, et al: The pathogenesis of melanoma induced by UV radiation. 340:1341-1348, 1999.
12. Hemminki K, Loonstedt I, Vaittinen, et al: Estimation of genetic and environmental components in colorectal and lung cancer and melanoma. Genet Epidemiol 20:107-116, 2001.
13. English DR, Armstrong BK, Kricker A, et al: Sunlight and cancer. Cancer Causes Control 8:271-283, 1997.
14. Wang SQ, Setlow R, Berwick M, et al: Ultraviolet A and melanoma: A review. J Am Acad Dermatol 44:837-846, 2001.
15. Camplejohn RS: DNA damage and repair in melanoma and nonmelanoma skin cancer. Cancer Surv 26:193-206, 1996.
16. Wolf P, Maier H, Mullegger RR, et al: Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor- [alpha]. J Invest Dermatol 114:149-156, 2000.
17. Puri N, Eller M, Byers R, et al: Telomere 3- overhang specific DNA induces apoptosis and differentiation in human melanoma cells in vitro and reduces their tumorigenicity in vivo. Proceedings of the Annual Society of Investigative Dermatology, Los Angeles, CA, May 14-17, 2002 (abstr).
18. Haluska FG, Hodi FS: Molecular genetics of familial cutaneous melanoma. J Clin Oncol 16:670-682, 1998.
19. Halachmi S, Gilchrest BA: Update on genetic events in the pathogenesis of melanoma. Curr Opin Oncol 13:129-136, 2001.
20. Blackwood MA, Holmes R, Synnestvedt M, et al: Multiple primary melanoma revisited. Cancer 94:2248-2255, 2002.
21. Winsey SL, Haldar NA, Marsh HP, et al: A variant of the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 60:5612-5616, 2000.
22. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-1733, 2000.
23. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 17:2941- 2953, 1999.
24. Karjalainen JM, Kellokoski JK, Eskelinen MJ et al: Down regulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 16:3584-3591, 1998.
25. Rizos H, Darmanian AP, Holland EA, et al: Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276:41424-41434, 2001.
26. Walker GJ, Hayward NK: P16INK4A and p14ARF tumour suppressors in melanoma: Lessons from the mouse. Lancet 359:7-8, 2002.
27. Randerson-Moor JA, Harland M, Williams S, et al: A germline deletion of p14(ARF) but not CNKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10:55-62, 2001.
28. Munger K: Disruption of oncogene/tumor suppressor networks during human carcinogenesis. Cancer Invest 20:71-81, 2002.
29. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochim Biochim Biophys Acta 1333:F51-F71, 1997.
30. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989.
31. Jiveskog S, Ragnarsson-Olding V, Platz A, et al: N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 111:757-761, 1998.
32. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954; 2002.
33. McGill GG, Horstmann M, Widlund HR, et al: Bc1-2 regulation by the melanocyte master regulator MITF modulates lineage survival and melanoma cell viability. Cell 109:707-718, 2002.
34. Kusewitt DF, Ley RD: Animal models in melanoma. Cancer Surv 25:35-70, 1996.
35. Rebel H, Mosnier LO, Berg RJW, et al: Early p53-positive foci as indicators of tumor risk in UV-exposed hairless mice. Cancer Res 61:977- 983, 2001.
36. Davol PA, Garza S, Frackleton AR: Combined suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model. Cancer 86:1733-1741, 1999.
37. Hursting SD, Slaga TJ, Fischer SM, et al: Mechanism-based cancer prevention approaches: Targets, examples and the use of transgenic mice. J Natl Cancer Inst 91:215-225, 1999.
38. Recio J, Merlino G, Noonan FP: A transgenic mouse model provides support for the critical role of juvenile UV exposure in initiation of cutaneous junctional melanoma. Proc Am Assoc Cancer Res 42:754, 2001.
39. Kato M, Liu W, Akhand AA, et al: Ultraviolet radiation induces both full activation of ret kinase and malignant melanocytic tumor promotion in RFP-RET-transgenic mice. J Invest Dermatol 115:1157-1158, 2000.
40. Yang J, Lual J, Yu Y, et al: Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/ARF. Cancer Res 61:8150-8157, 2001.
41. Lluria-Prevatt MC, Morreale J, Gregus J, et al: Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev 11:573, 2002.
42. Hawk E, Viner JL, Lawrence JA: Biomarkers for cancer development. Curr Oncol Rep 2:242-250, 2000.
43. Meyskens FL, Edwards L: Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol 15:822-825, 1986.
44. Edwards L, Jaffe P: The effect of topical tretinoin on dysplastic nevi. Arch Dermatol 126:494-499, 1990.
45. Halpern AC, Schucter LM, Elder DE, et al: Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 12:1028-1035, 1994.
46. Stam-Postuma JJ, Vink J, le Cessie S, et al: Effect of topical tretinoin under occlusion on atypical nevi. Melanoma Res 8:539-548, 1998.
47. Simoni D, Tolomeo M: Retinoids, apoptosis and cancer. Curr Pharm Des 7:1823-1837, 2001.
48. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast Group Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998.
49. Nathanson L: Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma. Cancer 91:881- 888, 2001(editorial).
50. Bloomfield Rubins H, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999.
51. Downs JR, Clearfielf M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279:1615-1622, 1998.
52. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996.
53. Dellavalle RP, Schilling LM: Do lipid-lowering drugs prevent melanoma? J Invest Dermatol 117:761, 2001 (abstr).
54. Ming M, Levy R, Lehrer M, et al: Effect of lipid-lowering drugs on the development of melanoma. Proc Soc of Invest Dermatol, Los Angeles, CA, May 14-17, 2002 (abstr).
55. DeClue JE, Vass WC, Papageorge AG, et al: Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51:712-717, 1991.
56. Jakobisiak M, Bruno S, Skierski JS, et al: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci U S A 88:3628-3632, 1991.
57. Xia Z, Tan MM, Wong WW, et al: Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15:1398-1407, 2001.
58. Feleszko W, Balkowiec EZ, Sieberth E, et al: Lovastatin and TNF-alpha exhibit potentiated antitumor effects against Ha-ras transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81:560-567, 1999.
59. Tamanoi F: Inhibitors of Ras farnesyltransferases. Trends Biochem Sci 18:349-353, 1993.
60. Marshall CJ: Protein prenylation: A mediator of protein-protein interactions. Science 259:1865-1866, 1993.
61. Mackie BS, Mackie LE, Curtin LD, et al: Melanoma and dietary lipids. Nutr Cancer 9:219-226, 1987.
62. Kirkpatrick CS, White E, Lee JAH: Case-control study of malignant melanoma in Washington State: II. Diet, alcohol, and obesity Am J Epidemiol 139:869-880, 1994.
63. Holman CDJ, Armstrong BK, Heenan PJ, et al: The causes of malignant melanoma: Results from the West Australian Lions Melanoma Research Project. Recent Results Cancer Res 102:18-37, 1986.
64. Osterlind A, Tucker MA, Stone BJ, et al: The Danish case-control study of cutaneous malignant melanoma: IV. No association with nutritional factors, alcohol, smoking or hair dyes. Int J Cancer 42:825-828, 1988.
65. Gallagher RP, Elwood JM, Hill GB: Risk factors for cutaneous malignant melanoma: The Western Canada Melanoma Study. Recent Results Cancer Res 102:38-55, 1986.
66. Bain C, Green A, Siskind Y, et al: Diet and melanoma: An exploratory case-control study. Ann Epidemiol 3:235-238, 1993.
67. Cohen LA, Albino AP: Polyunsaturated fatty acids and skin cancer: Part II. Cancer Res Alert, p 97-101, 2001.
68. Albino AP, Juan G, Traganos F, et al: Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: Association with decreased pRb phosphorylation. Cancer Res 60:4139-4145, 2000.
69. Rünger TM: Role of UVA in the pathogenesis of melanoma and non-melanoma skin cancer. Photodermatol Photoimmunol Photomed 15: 212-216, 1999.
70. Stryker WS, Stampfer MJ, Stein EA, et al: Diet, plasma levels of beta-carotene and alpha-tocopherol and risk of malignant melanoma. Am J Epidemiol 131:597-611, 1990.
71. Mahabir S, Coit D, Liebes L, et al: Randomized, placebo-controlled trial of dietary supplementation of alpha-tocopherol on mutagen sensitivity levels in melanoma patients: A pilot trial. Melanoma Res 12:83-90, 2002.
72. Kneckt P, Aromaa A, Maatela J, et al: Serum micronutrients and risk of cancers of low incidence in Finland. Am J Epidemiol 134:356-361, 1991.
73. McKenzie RC: Selenium, ultraviolet radiation and the skin. Clin Exp Dermatol 25:631-636, 2000.
74. Yan L, Yee JA, Li D, et al: Dietary supplementation of selenomethionine reduces metastasis of melanoma cells in mice. Anticancer Res 19:1337-1342, 1999.
75. Vinceti M, Rothman KJ, Bergomi M, et al: Excess melanoma incidence in a cohort exposed to high levels of environmental selenium. Cancer Epidemiol Biomarkers Prev 7:853-856, 1998.
76. Elmets CA, Singh D, Tubesing K, et al: Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol 44:425-432, 2001.
77. Record IR, Broadbent JL, King RA, et al: Genistein inhibits growth of B16 melanoma cells in vivo and in vitro and promotes differentiation in vitro. Int J Cancer 72:860-864, 1997.
78. Guo TL, McCay JA, Zhang LX, et al: Genistein modulates immune responses and increases host resistance to B16F10 tumor in adult female B6C3F1 mice. J Nutr 131:3251-3258, 2001.
79. Wei H: Photoprotective action of isoflavone genistein: Models, mechanisms, and relevance to clinical dermatology. J Am Acad Dermatol 39:271-272, 1998.
80. Perera FP: Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 88:496-509, 1996.
81. Kelloff GJ, Crowell JA, Steele VE, et al: Progress in cancer chemoprevention. Ann N Y Acad Sci 889:1-13, 1999.
82. Kelloff GJ, Crowell J, Steele VA, et al: Progress in clinical chemoprevention. Semin Oncol 24:241-252, 1997.
83. Stratton SP, Dorr RT, Alberts DS: The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer 36:1292-1297, 2000.
84. Bregman MD, Meyskens FL Jr: Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. Int J Cancer 37:101-107, 1986.
85. Meyskens FL, Kingsley EM, Glattke T, et al: A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest New Drugs 4:257-262, 1986.
86. Greenwald P: Cancer chemoprevention. BMJ 324:714-718, 2002.
87. Lupulescu A: Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54:83-94, 1996.
88. Williams CS, Mann M, DuBois RN: The role of cyclooxgenases in inflammation, cancer, and development. Oncogene 18:7908-7916, 1999.
89. Bakhle YS: COX-2 and cancer: A new approach to an old problem. Br J Pharmacol 134:1137-1150, 2001.
90. Denkert C, Kobel M, Berger S, et al: Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61:303-308, 2001.
91. Harris RE, Beebe-Donk J, Namboodiri KK: Inverse association of non-steroidal anti-inflammatory drugs in malignant melanoma among women. Oncol Rep 8:655-657, 2001.
92. Orengo IF, Gerguis J, Phillips R, et al: Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer. Arch Dermatol 138:751-755, 2002.
93. Broome Powell M, Alberts DS, Lluriat-Prevatt M, et al: Preclinical and clinical activity of apomine, a novel biophosphonate ester, in the prevention and treatment of melanoma. Proc Am Assoc Cancer Res 43:1007, 2002 (abstr 4992).
94. Barthelman M, Chen W, Gensler HL, et al: Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 58:711-716, 1998.
95. Curiel-Lewandrowski C, Demierre MF: Advances in specific immunotherapy of malignant melanoma. J Am Acad Dermatol 43:167-185, 2000.
96. Cleaver JE: Common pathways of ultraviolet skin carcinogenesis of the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci 23:1-11, 2000.
97. Kraemer KH, DiGiovanna JJ, Mashell AN, et al: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318:1633-1637, 1988.
98. Yarosh D, Klein J, O'Connor A, et al: Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomized study. Xeroderma Pigmentosum Study Group. Lancet 357:926- 929, 2001.
99. Baum CM: Preventing early steps leading to melanoma: Farnesyl transferase inhibitors. Treatment Reporter-Adv Melanoma Manag, 2000, pp 9.
100. Venet M, Angibaud P, Sanz G, et al: Synthesis and in-vitro structureactivity relationships of imidazolyl-2-quinolinones as farnesyl protein transferase inhibitors (FTI). Proc Am Assoc Cancer Res 39:318, 1998 (abstr).
101. Gajewski TF, Flickinger R, Heimann G, et al: Phase II study of the anti-angiogenic Flk-1 tyrosine kinase inhibitor SU5416 in melanoma: Initial results. Proc Am Soc Clin Oncol 20:360a, 2001 (abstr 1436).
102. Jansen B, Wacheck E, Heere-Ress C, et al: Clinical, pharmacologic study of genasense (G3139 bcl 2 antisense oligonucleotide) and dacarbazine (DTIC) in patients with malignant melanoma. Proc Am Soc Clin Oncol 2001:20:357a (abstr 1426).
103. Green A: Chemoprevention of skin cancer. Int Agency Res Cancer Sci Publ 136:111-119, 1996.